Charles Bennett to Medical Oncology
This is a "connection" page, showing publications Charles Bennett has written about Medical Oncology.
Connection Strength
3.152
-
End of an era for erythropoiesis-stimulating agents in oncology. Int J Cancer. 2020 05 15; 146(10):2829-2835.
Score: 0.627
-
Generic drugs in oncology - Authors' reply. Lancet Oncol. 2017 02; 18(2):e64.
Score: 0.507
-
The sound and the fury: financial conflicts of interest in oncology. J Clin Oncol. 2007 Aug 20; 25(24):3567-9.
Score: 0.263
-
Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries. Am J Med. 2004 Jan 01; 116(1):28-34.
Score: 0.205
-
Perspectives on the value of American Society of Clinical Oncology clinical guidelines as reported by oncologists and health maintenance organizations. J Clin Oncol. 2003 Mar 01; 21(5):937-41.
Score: 0.193
-
Quality improvement efforts in oncology: are we ready to begin? Cancer Invest. 2001; 19(1):86-95.
Score: 0.166
-
Comparing cost-effectiveness analyses for the clinical oncology setting: the example of the Gynecologic Oncology Group 111 trial. Cancer Invest. 2000; 18(3):261-8.
Score: 0.155
-
Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA. 1999 Oct 20; 282(15):1453-7.
Score: 0.153
-
Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions. PLoS One. 2019; 14(7):e0219521.
Score: 0.151
-
A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer. World J Urol. 2019 Oct; 37(10):2099-2108.
Score: 0.145
-
Erythropoiesis-stimulating agents and quality of life: personal journeys of a cancer survivor, oncologist, and two cancer health services researchers. Br J Cancer. 2014 Jul 29; 111(3):421-3.
Score: 0.106
-
Thromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: a review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012 Nov; 38(8):759-67.
Score: 0.094
-
Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Oct; 4(9):838-69.
Score: 0.062
-
A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians. Gynecol Oncol. 2004 Apr; 93(1):164-9.
Score: 0.052
-
Purchasing oncology services. Kerr L. White Institute/American Cancer Society Task Force on Purchasing Oncology Services. Cancer. 2000 Jun 15; 88(12):2876-86.
Score: 0.040
-
Does reimbursement affect physician decision making? Cancer Treat Res. 2000; 102:137-49.
Score: 0.039
-
Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology. J Clin Oncol. 1999 Nov; 17(11):3676-81.
Score: 0.038
-
The association between physician reimbursement in the US and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: results from the 1997 American Society of Clinical Oncology survey. Health Services Research Committee of the American Society of Clinical Oncology. Ann Oncol. 1999 Nov; 10(11):1355-9.
Score: 0.038
-
Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists. Gynecol Oncol. 1998 Dec; 71(3):369-75.
Score: 0.036
-
Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology. J Clin Oncol. 1996 Sep; 14(9):2511-20.
Score: 0.031
-
Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance. Urol Oncol. 2014 Jan; 32(1):26.e25-31.
Score: 0.024
-
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood. 2008 Jan 01; 111(1):25-41.
Score: 0.017
-
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000 Oct 15; 18(20):3558-85.
Score: 0.010